Engagements

Shire acquisition of Dyax

In the US, we advised counsel to Shire on its acquisition of Dyax, a small pharmaceutical company with pipeline products to treat hereditary angioedema (HAE). The deal, reviewed by the FTC, closed with no divestitures.

Related Capabilities

Life Sciences
Mergers & Acquisitions

Andrew R. Dick
Vice President

Washington, DC
+1-202-662-3898 adick@crai.com
Peter Boberg
Vice President

Boston
+1-617-425-3175 pboberg@crai.com

Management Consulting
CRA Insights

Large scale and complex energy deals: Five priorities to drive success post-close

Up to 90% of M&A deals are regarded as failures and 83% of M&A deals fail to boost shareholder returns. Post-transaction playbooks are a known tool, helpful in...
Mergers & Acquisitions
Articles

The New Vertical Merger Guidelines: Muddying the Waters

The new US Department of Justice and Federal Trade Commission Vertical Merger Guidelines focus on how vertical mergers are likely to affect static pricing...

Explore our thinking

Shire acquisition of Dyax

Meet Our Team

Related Insights

Large scale and complex energy deals: Five priorities to drive success post-close

The New Vertical Merger Guidelines: Muddying the Waters